APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oxaliplatin

Oxaliplatin is a platinum-based anticancer drug with colorless or nearly colorless transparent liquid. It is often used for metastatic colorectal cancer treatment or adjuvant therapy the third stage colon cancer after resecting primary tumor completely.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Oxaliplatin is a platinum-based anticancer drug with colorless or nearly colorless transparent liquid. It is often used for metastatic colorectal cancer treatment or adjuvant therapy the third stage colon cancer after resecting primary tumor completely.

In this report, only the finished drug is covered, exclude API.

Selected research

Market Analysis & Forecast

Global Oxaliplatin Market Analysis and Forecast 2026-2032

22 December 2025208 pages

Choose your research edition.

Industry ResearchOxaliplatin Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Oxaliplatin Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Oxaliplatin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oxaliplatin Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Oxaliplatin Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

Oxaliplatin is a platinum-based anticancer drug with colorless or nearly colorless transparent liquid. It is often used for metastatic colorectal cancer treatment or adjuvant therapy the third stage colon cancer after resecting primary tumor completely.

In this report, only the finished drug is covered, exclude API.

Europe is the largest market with about 33% market share. Followed by Japan, accounting for about 30% revenue market share.

Read the full market overview

The key players are Sanofi-Aventis, Yakult honsha, Dr Reddy's laboratories, Sun Pharmaceutical, Teva, Fresenius Kabi, Hospira, Mylan, Jiangsu Hengrui Medicine, Nanjing Pharmaceutical Factory, Jiangsu Aosaikang Pharmaceutical, Qilu Pharmaceutical, Hisun Pharmaceutical, Lunan Pharmaceutical, Luoxin, Halfsky Pharmacy, YRPG, Hainan Jinrui Pharmaceutical, Jari Pharmaceutical, Chiatai Tianqing etc. Top 3 companies occupied about 66% revenue market share.

Report Includes

This report presents an overview of global market for Oxaliplatin, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Oxaliplatin, also provides the revenue of main regions and countries. Of the upcoming market potential for Oxaliplatin, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Oxaliplatin revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Oxaliplatin market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Oxaliplatin revenue, projected growth trends, production technology, application and end-user industry.

Oxaliplatin Segment by Company

Sanofi-Aventis

Yakult honsha

Dr Reddy's laboratories

Sun Pharmaceutical

Teva

Fresenius Kabi

Hospira

Mylan

Jiangsu Hengrui Medicine

Nanjing Pharmaceutical Factory

Jiangsu Aosaikang Pharmaceutical

Qilu Pharmaceutical

Hisun Pharmaceutical

Lunan Pharmaceutical

Luoxin

Halfsky Pharmacy

YRPG

Hainan Jinrui Pharmaceutical

Jari Pharmaceutical

Chiatai Tianqing

Oxaliplatin Segment by Type

Mannitol

Glucose Solution

Lactose Solution

Others

Oxaliplatin Segment by Application

Colorectal Cancer

Stomach Cancer

Ovarian Cancer

Others

Oxaliplatin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oxaliplatin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oxaliplatin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oxaliplatin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Oxaliplatin in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Oxaliplatin company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oxaliplatin revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Oxaliplatin Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Mannitol Major Player Table 3. Glucose Solution Major Player Table 4. Lactose Solution Major Player Table 5. Others Major Player Table 6. Global Oxaliplatin Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Colorectal Cancer Major Player Table 8. Stomach Cancer Major Player Table 9. Ovarian Cancer Major Player Table 10. Others Major Player Table 11. Oxaliplatin Industry Trends Table 12. Oxaliplatin Industry Drivers Table 13. Oxaliplatin Industry Opportunities and Challenges Table 14. Oxaliplatin Industry Restraints Table 15. Global Oxaliplatin Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Oxaliplatin Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Oxaliplatin Market Share by Region (2021-2026) Table 18. Global Oxaliplatin Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Oxaliplatin Market Share by Region (2027-2032) Table 20. Global Oxaliplatin Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Oxaliplatin Revenue Market Share by Players (2021-2026) Table 22. Global Oxaliplatin Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Oxaliplatin Key Players Headquarters & Area Served Table 24. Global Oxaliplatin Players, Product Type & Application Table 25. Global Oxaliplatin Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Oxaliplatin by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Oxaliplatin Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Oxaliplatin Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Oxaliplatin Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Oxaliplatin Revenue Market Share by Type (2021-2026) Table 32. Global Oxaliplatin Revenue Market Share by Type (2027-2032) Table 33. Global Oxaliplatin Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Oxaliplatin Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Oxaliplatin Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Oxaliplatin Revenue Market Share by Application (2021-2026) Table 37. Global Oxaliplatin Revenue Market Share by Application (2027-2032) Table 38. Sanofi-Aventis Company Information Table 39. Sanofi-Aventis Business Overview Table 40. Sanofi-Aventis Oxaliplatin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Sanofi-Aventis Oxaliplatin Product Portfolio Table 42. Sanofi-Aventis Recent Development Table 43. Yakult honsha Company Information Table 44. Yakult honsha Business Overview Table 45. Yakult honsha Oxaliplatin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Yakult honsha Oxaliplatin Product Portfolio Table 47. Yakult honsha Recent Development Table 48. Dr Reddy's laboratories Company Information Table 49. Dr Reddy's laboratories Business Overview Table 50. Dr Reddy's laboratories Oxaliplatin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Dr Reddy's laboratories Oxaliplatin Product Portfolio Table 52. Dr Reddy's laboratories Recent Development Table 53. Sun Pharmaceutical Company Information Table 54. Sun Pharmaceutical Business Overview Table 55. Sun Pharmaceutical Oxaliplatin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Sun Pharmaceutical Oxaliplatin Product Portfolio Table 57. Sun Pharmaceutical Recent Development Table 58. Teva Company Information Table 59. Teva Business Overview Table 60. Teva Oxaliplatin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Teva Oxaliplatin Product Portfolio Table 62. Teva Recent Development Table 63. Fresenius Kabi Company Information Table 64. Fresenius Kabi Business Overview Table 65. Fresenius Kabi Oxaliplatin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Fresenius Kabi Oxaliplatin Product Portfolio Table 67. Fresenius Kabi Recent Development Table 68. Hospira Company Information Table 69. Hospira Business Overview Table 70. Hospira Oxaliplatin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Hospira Oxaliplatin Product Portfolio Table 72. Hospira Recent Development Table 73. Mylan Company Information Table 74. Mylan Business Overview Table 75. Mylan Oxaliplatin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Mylan Oxaliplatin Product Portfolio Table 77. Mylan Recent Development Table 78. Jiangsu Hengrui Medicine Company Information Table 79. Jiangsu Hengrui Medicine Business Overview Table 80. Jiangsu Hengrui Medicine Oxaliplatin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Jiangsu Hengrui Medicine Oxaliplatin Product Portfolio Table 82. Jiangsu Hengrui Medicine Recent Development Table 83. Nanjing Pharmaceutical Factory Company Information Table 84. Nanjing Pharmaceutical Factory Business Overview Table 85. Nanjing Pharmaceutical Factory Oxaliplatin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Nanjing Pharmaceutical Factory Oxaliplatin Product Portfolio Table 87. Nanjing Pharmaceutical Factory Recent Development Table 88. Jiangsu Aosaikang Pharmaceutical Company Information Table 89. Jiangsu Aosaikang Pharmaceutical Business Overview Table 90. Jiangsu Aosaikang Pharmaceutical Oxaliplatin Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 91. Jiangsu Aosaikang Pharmaceutical Oxaliplatin Product Portfolio Table 92. Jiangsu Aosaikang Pharmaceutical Recent Development Table 93. Qilu Pharmaceutical Company Information Table 94. Qilu Pharmaceutical Business Overview Table 95. Qilu Pharmaceutical Oxaliplatin Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 96. Qilu Pharmaceutical Oxaliplatin Product Portfolio Table 97. Qilu Pharmaceutical Recent Development Table 98. Hisun Pharmaceutical Company Information Table 99. Hisun Pharmaceutical Business Overview Table 100. Hisun Pharmaceutical Oxaliplatin Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 101. Hisun Pharmaceutical Oxaliplatin Product Portfolio Table 102. Hisun Pharmaceutical Recent Development Table 103. Lunan Pharmaceutical Company Information Table 104. Lunan Pharmaceutical Business Overview Table 105. Lunan Pharmaceutical Oxaliplatin Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 106. Lunan Pharmaceutical Oxaliplatin Product Portfolio Table 107. Lunan Pharmaceutical Recent Development Table 108. Luoxin Company Information Table 109. Luoxin Business Overview Table 110. Luoxin Oxaliplatin Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 111. Luoxin Oxaliplatin Product Portfolio Table 112. Luoxin Recent Development Table 113. Halfsky Pharmacy Company Information Table 114. Halfsky Pharmacy Business Overview Table 115. Halfsky Pharmacy Oxaliplatin Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 116. Halfsky Pharmacy Oxaliplatin Product Portfolio Table 117. Halfsky Pharmacy Recent Development Table 118. YRPG Company Information Table 119. YRPG Business Overview Table 120. YRPG Oxaliplatin Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 121. YRPG Oxaliplatin Product Portfolio Table 122. YRPG Recent Development Table 123. Hainan Jinrui Pharmaceutical Company Information Table 124. Hainan Jinrui Pharmaceutical Business Overview Table 125. Hainan Jinrui Pharmaceutical Oxaliplatin Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 126. Hainan Jinrui Pharmaceutical Oxaliplatin Product Portfolio Table 127. Hainan Jinrui Pharmaceutical Recent Development Table 128. Jari Pharmaceutical Company Information Table 129. Jari Pharmaceutical Business Overview Table 130. Jari Pharmaceutical Oxaliplatin Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 131. Jari Pharmaceutical Oxaliplatin Product Portfolio Table 132. Jari Pharmaceutical Recent Development Table 133. Chiatai Tianqing Company Information Table 134. Chiatai Tianqing Business Overview Table 135. Chiatai Tianqing Oxaliplatin Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 136. Chiatai Tianqing Oxaliplatin Product Portfolio Table 137. Chiatai Tianqing Recent Development Table 138. North America Oxaliplatin Revenue by Type (2021-2026) & (US$ Million) Table 139. North America Oxaliplatin Revenue by Type (2027-2032) & (US$ Million) Table 140. North America Oxaliplatin Revenue by Application (2021-2026) & (US$ Million) Table 141. North America Oxaliplatin Revenue by Application (2027-2032) & (US$ Million) Table 142. North America Oxaliplatin Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 143. North America Oxaliplatin Revenue by Country (2021-2026) & (US$ Million) Table 144. North America Oxaliplatin Revenue by Country (US$ Million) & (2027-2032) Table 145. Europe Oxaliplatin Revenue by Type (2021-2026) & (US$ Million) Table 146. Europe Oxaliplatin Revenue by Type (2027-2032) & (US$ Million) Table 147. Europe Oxaliplatin Revenue by Application (2021-2026) & (US$ Million) Table 148. Europe Oxaliplatin Revenue by Application (2027-2032) & (US$ Million) Table 149. Europe Oxaliplatin Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 150. Europe Oxaliplatin Revenue by Country (2021-2026) & (US$ Million) Table 151. Europe Oxaliplatin Revenue by Country (US$ Million) & (2027-2032) Table 152. China Oxaliplatin Revenue by Type (2021-2026) & (US$ Million) Table 153. China Oxaliplatin Revenue by Type (2027-2032) & (US$ Million) Table 154. China Oxaliplatin Revenue by Application (2021-2026) & (US$ Million) Table 155. China Oxaliplatin Revenue by Application (2027-2032) & (US$ Million) Table 156. Asia Oxaliplatin Revenue by Type (2021-2026) & (US$ Million) Table 157. Asia Oxaliplatin Revenue by Type (2027-2032) & (US$ Million) Table 158. Asia Oxaliplatin Revenue by Application (2021-2026) & (US$ Million) Table 159. Asia Oxaliplatin Revenue by Application (2027-2032) & (US$ Million) Table 160. Asia Oxaliplatin Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 161. Asia Oxaliplatin Revenue by Region (US$ Million) & (2021-2026) Table 162. Asia Oxaliplatin Revenue by Region (US$ Million) & (2027-2032) Table 163. SAMEA Oxaliplatin Revenue by Type (2021-2026) & (US$ Million) Table 164. SAMEA Oxaliplatin Revenue by Type (2027-2032) & (US$ Million) Table 165. SAMEA Oxaliplatin Revenue by Application (2021-2026) & (US$ Million) Table 166. SAMEA Oxaliplatin Revenue by Application (2027-2032) & (US$ Million) Table 167. SAMEA Oxaliplatin Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 168. SAMEA Oxaliplatin Revenue by Country (2021-2026) & (US$ Million) Table 169. SAMEA Oxaliplatin Revenue by Country (US$ Million) & (2027-2032) Table 170. Research Programs/Design for This Report Table 171. Authors List of This Report Table 172. Secondary Sources Table 173. Primary Sources List of Figures Figure 1. Oxaliplatin Image Figure 2. Global Oxaliplatin Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oxaliplatin Market Size Share 2021 VS 2025 VS 2032 Figure 4. Mannitol Image Figure 5. Glucose Solution Image Figure 6. Lactose Solution Image Figure 7. Others Image Figure 8. Global Oxaliplatin Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Oxaliplatin Market Size Share 2021 VS 2025 VS 2032 Figure 10. Colorectal Cancer Image Figure 11. Stomach Cancer Image Figure 12. Ovarian Cancer Image Figure 13. Others Image Figure 14. Global Oxaliplatin Market Size (US$ Million) & (2021-2032) Figure 15. Global Oxaliplatin Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Oxaliplatin Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Oxaliplatin Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Oxaliplatin Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Oxaliplatin Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Oxaliplatin Revenue Market Share by Type (2021-2032) Figure 22. Global Oxaliplatin Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Oxaliplatin Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Oxaliplatin Revenue Market Share by Application (2021-2032) Figure 25. North America Oxaliplatin Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Oxaliplatin Revenue Share by Type (2021-2032) Figure 27. North America Oxaliplatin Revenue Share by Application (2021-2032) Figure 28. North America Oxaliplatin Revenue Share by Country (2021-2032) Figure 29. United States Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Oxaliplatin Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Oxaliplatin Revenue Share by Type (2021-2032) Figure 34. Europe Oxaliplatin Revenue Share by Application (2021-2032) Figure 35. Europe Oxaliplatin Revenue Share by Country (2021-2032) Figure 36. Germany Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Oxaliplatin Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Oxaliplatin Revenue Share by Type (2021-2032) Figure 46. China Oxaliplatin Revenue Share by Application (2021-2032) Figure 47. Asia Oxaliplatin Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Oxaliplatin Revenue Share by Type (2021-2032) Figure 49. Asia Oxaliplatin Revenue Share by Application (2021-2032) Figure 50. Asia Oxaliplatin Revenue Share by Region (2021-2032) Figure 51. Japan Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Oxaliplatin Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Oxaliplatin Revenue Share by Type (2021-2032) Figure 59. SAMEA Oxaliplatin Revenue Share by Application (2021-2032) Figure 60. SAMEA Oxaliplatin Revenue Share by Country (2021-2032) Figure 61. Brazil Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Oxaliplatin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Mannitol
  • Glucose Solution
  • Lactose Solution
  • Others
Applications
  • Colorectal Cancer
  • Stomach Cancer
  • Ovarian Cancer
  • Others
Companies covered
  • Sanofi-Aventis
  • Yakult honsha
  • Dr Reddy's laboratories
  • Sun Pharmaceutical
  • Teva
  • Fresenius Kabi
  • Hospira
  • Mylan
  • Jiangsu Hengrui Medicine
  • Nanjing Pharmaceutical Factory
  • Jiangsu Aosaikang Pharmaceutical
  • Qilu Pharmaceutical
  • Hisun Pharmaceutical
  • Lunan Pharmaceutical
  • Luoxin
  • Halfsky Pharmacy
  • YRPG
  • Hainan Jinrui Pharmaceutical
  • Jari Pharmaceutical
  • Chiatai Tianqing

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Oxaliplatin Market by Type
  3. 1.2.1 Global Oxaliplatin Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Mannitol
  5. 1.2.3 Glucose Solution
  6. 1.2.4 Lactose Solution
  7. 1.2.5 Others
  8. 1.3 Oxaliplatin Market by Application
  9. 1.3.1 Global Oxaliplatin Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Colorectal Cancer
  11. 1.3.3 Stomach Cancer
  12. 1.3.4 Ovarian Cancer
  13. 1.3.5 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Oxaliplatin Market Dynamics
  1. 2.1 Oxaliplatin Industry Trends
  2. 2.2 Oxaliplatin Industry Drivers
  3. 2.3 Oxaliplatin Industry Opportunities and Challenges
  4. 2.4 Oxaliplatin Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Oxaliplatin Market Perspective (2021-2032)
  2. 3.2 Global Oxaliplatin Growth Trends by Region
  3. 3.2.1 Global Oxaliplatin Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Oxaliplatin Market Size by Region (2021-2026)
  5. 3.2.3 Global Oxaliplatin Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Oxaliplatin Revenue by Players
  2. 4.1.1 Global Oxaliplatin Revenue by Players (2021-2026)
  3. 4.1.2 Global Oxaliplatin Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Oxaliplatin Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Oxaliplatin Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Oxaliplatin Key Players Headquarters & Area Served
  7. 4.4 Global Oxaliplatin Players, Product Type & Application
  8. 4.5 Global Oxaliplatin Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Oxaliplatin Market CR5 and HHI
  11. 4.6.3 2025 Oxaliplatin Tier 1, Tier 2, and Tier 3
5 Oxaliplatin Market Size by Type
  1. 5.1 Global Oxaliplatin Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Oxaliplatin Revenue by Type (2021-2032)
  3. 5.3 Global Oxaliplatin Revenue Market Share by Type (2021-2032)
6 Oxaliplatin Market Size by Application
  1. 6.1 Global Oxaliplatin Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Oxaliplatin Revenue by Application (2021-2032)
  3. 6.3 Global Oxaliplatin Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sanofi-Aventis
  2. 7.1.1 Sanofi-Aventis Company Information
  3. 7.1.2 Sanofi-Aventis Business Overview
  4. 7.1.3 Sanofi-Aventis Oxaliplatin Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi-Aventis Oxaliplatin Product Portfolio
  6. 7.1.5 Sanofi-Aventis Recent Developments
  7. 7.2 Yakult honsha
  8. 7.2.1 Yakult honsha Company Information
  9. 7.2.2 Yakult honsha Business Overview
  10. 7.2.3 Yakult honsha Oxaliplatin Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Yakult honsha Oxaliplatin Product Portfolio
  12. 7.2.5 Yakult honsha Recent Developments
  13. 7.3 Dr Reddy's laboratories
  14. 7.3.1 Dr Reddy's laboratories Company Information
  15. 7.3.2 Dr Reddy's laboratories Business Overview
  16. 7.3.3 Dr Reddy's laboratories Oxaliplatin Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Dr Reddy's laboratories Oxaliplatin Product Portfolio
  18. 7.3.5 Dr Reddy's laboratories Recent Developments
  19. 7.4 Sun Pharmaceutical
  20. 7.4.1 Sun Pharmaceutical Company Information
  21. 7.4.2 Sun Pharmaceutical Business Overview
  22. 7.4.3 Sun Pharmaceutical Oxaliplatin Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Sun Pharmaceutical Oxaliplatin Product Portfolio
  24. 7.4.5 Sun Pharmaceutical Recent Developments
  25. 7.5 Teva
  26. 7.5.1 Teva Company Information
  27. 7.5.2 Teva Business Overview
  28. 7.5.3 Teva Oxaliplatin Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Teva Oxaliplatin Product Portfolio
  30. 7.5.5 Teva Recent Developments
  31. 7.6 Fresenius Kabi
  32. 7.6.1 Fresenius Kabi Company Information
  33. 7.6.2 Fresenius Kabi Business Overview
  34. 7.6.3 Fresenius Kabi Oxaliplatin Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Fresenius Kabi Oxaliplatin Product Portfolio
  36. 7.6.5 Fresenius Kabi Recent Developments
  37. 7.7 Hospira
  38. 7.7.1 Hospira Company Information
  39. 7.7.2 Hospira Business Overview
  40. 7.7.3 Hospira Oxaliplatin Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Hospira Oxaliplatin Product Portfolio
  42. 7.7.5 Hospira Recent Developments
  43. 7.8 Mylan
  44. 7.8.1 Mylan Company Information
  45. 7.8.2 Mylan Business Overview
  46. 7.8.3 Mylan Oxaliplatin Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Mylan Oxaliplatin Product Portfolio
  48. 7.8.5 Mylan Recent Developments
  49. 7.9 Jiangsu Hengrui Medicine
  50. 7.9.1 Jiangsu Hengrui Medicine Company Information
  51. 7.9.2 Jiangsu Hengrui Medicine Business Overview
  52. 7.9.3 Jiangsu Hengrui Medicine Oxaliplatin Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Jiangsu Hengrui Medicine Oxaliplatin Product Portfolio
  54. 7.9.5 Jiangsu Hengrui Medicine Recent Developments
  55. 7.10 Nanjing Pharmaceutical Factory
  56. 7.10.1 Nanjing Pharmaceutical Factory Company Information
  57. 7.10.2 Nanjing Pharmaceutical Factory Business Overview
  58. 7.10.3 Nanjing Pharmaceutical Factory Oxaliplatin Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Nanjing Pharmaceutical Factory Oxaliplatin Product Portfolio
  60. 7.10.5 Nanjing Pharmaceutical Factory Recent Developments
  61. 7.11 Jiangsu Aosaikang Pharmaceutical
  62. 7.11.1 Jiangsu Aosaikang Pharmaceutical Company Information
  63. 7.11.2 Jiangsu Aosaikang Pharmaceutical Business Overview
  64. 7.11.3 Jiangsu Aosaikang Pharmaceutical Oxaliplatin Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Jiangsu Aosaikang Pharmaceutical Oxaliplatin Product Portfolio
  66. 7.11.5 Jiangsu Aosaikang Pharmaceutical Recent Developments
  67. 7.12 Qilu Pharmaceutical
  68. 7.12.1 Qilu Pharmaceutical Company Information
  69. 7.12.2 Qilu Pharmaceutical Business Overview
  70. 7.12.3 Qilu Pharmaceutical Oxaliplatin Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Qilu Pharmaceutical Oxaliplatin Product Portfolio
  72. 7.12.5 Qilu Pharmaceutical Recent Developments
  73. 7.13 Hisun Pharmaceutical
  74. 7.13.1 Hisun Pharmaceutical Company Information
  75. 7.13.2 Hisun Pharmaceutical Business Overview
  76. 7.13.3 Hisun Pharmaceutical Oxaliplatin Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Hisun Pharmaceutical Oxaliplatin Product Portfolio
  78. 7.13.5 Hisun Pharmaceutical Recent Developments
  79. 7.14 Lunan Pharmaceutical
  80. 7.14.1 Lunan Pharmaceutical Company Information
  81. 7.14.2 Lunan Pharmaceutical Business Overview
  82. 7.14.3 Lunan Pharmaceutical Oxaliplatin Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Lunan Pharmaceutical Oxaliplatin Product Portfolio
  84. 7.14.5 Lunan Pharmaceutical Recent Developments
  85. 7.15 Luoxin
  86. 7.15.1 Luoxin Company Information
  87. 7.15.2 Luoxin Business Overview
  88. 7.15.3 Luoxin Oxaliplatin Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Luoxin Oxaliplatin Product Portfolio
  90. 7.15.5 Luoxin Recent Developments
  91. 7.16 Halfsky Pharmacy
  92. 7.16.1 Halfsky Pharmacy Company Information
  93. 7.16.2 Halfsky Pharmacy Business Overview
  94. 7.16.3 Halfsky Pharmacy Oxaliplatin Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Halfsky Pharmacy Oxaliplatin Product Portfolio
  96. 7.16.5 Halfsky Pharmacy Recent Developments
  97. 7.17 YRPG
  98. 7.17.1 YRPG Company Information
  99. 7.17.2 YRPG Business Overview
  100. 7.17.3 YRPG Oxaliplatin Revenue and Gross Margin (2021-2026)
  101. 7.17.4 YRPG Oxaliplatin Product Portfolio
  102. 7.17.5 YRPG Recent Developments
  103. 7.18 Hainan Jinrui Pharmaceutical
  104. 7.18.1 Hainan Jinrui Pharmaceutical Company Information
  105. 7.18.2 Hainan Jinrui Pharmaceutical Business Overview
  106. 7.18.3 Hainan Jinrui Pharmaceutical Oxaliplatin Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Hainan Jinrui Pharmaceutical Oxaliplatin Product Portfolio
  108. 7.18.5 Hainan Jinrui Pharmaceutical Recent Developments
  109. 7.19 Jari Pharmaceutical
  110. 7.19.1 Jari Pharmaceutical Company Information
  111. 7.19.2 Jari Pharmaceutical Business Overview
  112. 7.19.3 Jari Pharmaceutical Oxaliplatin Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Jari Pharmaceutical Oxaliplatin Product Portfolio
  114. 7.19.5 Jari Pharmaceutical Recent Developments
  115. 7.20 Chiatai Tianqing
  116. 7.20.1 Chiatai Tianqing Company Information
  117. 7.20.2 Chiatai Tianqing Business Overview
  118. 7.20.3 Chiatai Tianqing Oxaliplatin Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Chiatai Tianqing Oxaliplatin Product Portfolio
  120. 7.20.5 Chiatai Tianqing Recent Developments
8 North America
  1. 8.1 North America Oxaliplatin Revenue (2021-2032)
  2. 8.2 North America Oxaliplatin Revenue by Type (2021-2032)
  3. 8.2.1 North America Oxaliplatin Revenue by Type (2021-2026)
  4. 8.2.2 North America Oxaliplatin Revenue by Type (2027-2032)
  5. 8.3 North America Oxaliplatin Revenue Share by Type (2021-2032)
  6. 8.4 North America Oxaliplatin Revenue by Application (2021-2032)
  7. 8.4.1 North America Oxaliplatin Revenue by Application (2021-2026)
  8. 8.4.2 North America Oxaliplatin Revenue by Application (2027-2032)
  9. 8.5 North America Oxaliplatin Revenue Share by Application (2021-2032)
  10. 8.6 North America Oxaliplatin Revenue by Country
  11. 8.6.1 North America Oxaliplatin Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Oxaliplatin Revenue by Country (2021-2026)
  13. 8.6.3 North America Oxaliplatin Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Oxaliplatin Revenue (2021-2032)
  2. 9.2 Europe Oxaliplatin Revenue by Type (2021-2032)
  3. 9.2.1 Europe Oxaliplatin Revenue by Type (2021-2026)
  4. 9.2.2 Europe Oxaliplatin Revenue by Type (2027-2032)
  5. 9.3 Europe Oxaliplatin Revenue Share by Type (2021-2032)
  6. 9.4 Europe Oxaliplatin Revenue by Application (2021-2032)
  7. 9.4.1 Europe Oxaliplatin Revenue by Application (2021-2026)
  8. 9.4.2 Europe Oxaliplatin Revenue by Application (2027-2032)
  9. 9.5 Europe Oxaliplatin Revenue Share by Application (2021-2032)
  10. 9.6 Europe Oxaliplatin Revenue by Country
  11. 9.6.1 Europe Oxaliplatin Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Oxaliplatin Revenue by Country (2021-2026)
  13. 9.6.3 Europe Oxaliplatin Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Oxaliplatin Revenue (2021-2032)
  2. 10.2 China Oxaliplatin Revenue by Type (2021-2032)
  3. 10.2.1 China Oxaliplatin Revenue by Type (2021-2026)
  4. 10.2.2 China Oxaliplatin Revenue by Type (2027-2032)
  5. 10.3 China Oxaliplatin Revenue Share by Type (2021-2032)
  6. 10.4 China Oxaliplatin Revenue by Application (2021-2032)
  7. 10.4.1 China Oxaliplatin Revenue by Application (2021-2026)
  8. 10.4.2 China Oxaliplatin Revenue by Application (2027-2032)
  9. 10.5 China Oxaliplatin Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Oxaliplatin Revenue (2021-2032)
  2. 11.2 Asia Oxaliplatin Revenue by Type (2021-2032)
  3. 11.2.1 Asia Oxaliplatin Revenue by Type (2021-2026)
  4. 11.2.2 Asia Oxaliplatin Revenue by Type (2027-2032)
  5. 11.3 Asia Oxaliplatin Revenue Share by Type (2021-2032)
  6. 11.4 Asia Oxaliplatin Revenue by Application (2021-2032)
  7. 11.4.1 Asia Oxaliplatin Revenue by Application (2021-2026)
  8. 11.4.2 Asia Oxaliplatin Revenue by Application (2027-2032)
  9. 11.5 Asia Oxaliplatin Revenue Share by Application (2021-2032)
  10. 11.6 Asia Oxaliplatin Revenue by Country
  11. 11.6.1 Asia Oxaliplatin Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Oxaliplatin Revenue by Country (2021-2026)
  13. 11.6.3 Asia Oxaliplatin Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Oxaliplatin Revenue (2021-2032)
  2. 12.2 SAMEA Oxaliplatin Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Oxaliplatin Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Oxaliplatin Revenue by Type (2027-2032)
  5. 12.3 SAMEA Oxaliplatin Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Oxaliplatin Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Oxaliplatin Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Oxaliplatin Revenue by Application (2027-2032)
  9. 12.5 SAMEA Oxaliplatin Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Oxaliplatin Revenue by Country
  11. 12.6.1 SAMEA Oxaliplatin Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Oxaliplatin Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Oxaliplatin Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst